Literature DB >> 22031855

Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat.

Christine Maric-Bilkan1, Elizabeth R Flynn, Alejandro R Chade.   

Abstract

Diabetic nephropathy is a progressive and generalized vasculopathic condition associated with abnormal angiogenesis. We aim to determine whether changes in renal microvascular (MV) density correlate with and play a role in the progressive deterioration of renal function in diabetes. We hypothesize that MV changes represent the early steps of renal injury that worsen as diabetes progresses, initiating a vicious circle that leads to irreversible renal injury. Male nondiabetic (ND) or streptozotocin-induced diabetic (D) Sprague-Dawley rats were followed for 4 or 12 wk. Renal blood flow and glomerular filtration rate (GFR) were measured by PAH and (125)I-[iothalamate], respectively. Renal MV density was quantified ex vivo using three-dimensional micro computed tomography and JG-12 immunoreactivity. Vascular endothelial growth factor (VEGF) levels (ELISA) and expression of VEGF receptors and factors involved in MV remodeling were quantified in renal tissue by Western blotting. Finally, renal morphology was investigated by histology. Four weeks of diabetes was associated with increased GFR, accompanied by a 34% reduction in renal MV density and augmented renal VEGF levels. However, at 12 wk, while GFR remained similarly elevated, reduction of MV density was more pronounced (75%) and associated with increased MV remodeling, renal fibrosis, but unchanged renal VEGF compared with ND at 12 wk. The damage, loss, and subsequent remodeling of the renal MV architecture in the diabetic kidney may represent the initiating events of progressive renal injury. This study suggests a novel concept of MV disease as an early instigator of diabetic kidney disease that may precede and likely promote the decline in renal function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22031855      PMCID: PMC3287355          DOI: 10.1152/ajprenal.00421.2011

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  30 in total

1.  New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy.

Authors:  R Osterby; G Nyberg
Journal:  J Diabet Complications       Date:  1987 Oct-Dec

2.  17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney.

Authors:  Richard W Mankhey; Corinne C Wells; Faizah Bhatti; Christine Maric
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-08-24       Impact factor: 3.619

Review 3.  Pathogenesis of diabetic nephropathy.

Authors:  A E Raptis; G Viberti
Journal:  Exp Clin Endocrinol Diabetes       Date:  2001       Impact factor: 2.949

Review 4.  The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.

Authors:  T H Hostetter; H G Rennke; B M Brenner
Journal:  Am J Med       Date:  1982-03       Impact factor: 4.965

5.  Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy.

Authors:  Maja T Lindenmeyer; Matthias Kretzler; Anissa Boucherot; Silvia Berra; Yoshinari Yasuda; Anna Henger; Felix Eichinger; Stefanie Gaiser; Holger Schmid; Maria P Rastaldi; Robert W Schrier; Detlef Schlöndorff; Clemens D Cohen
Journal:  J Am Soc Nephrol       Date:  2007-05-02       Impact factor: 10.121

6.  Abnormal angiogenesis in diabetic nephropathy.

Authors:  Takahiko Nakagawa; Tomoki Kosugi; Masakazu Haneda; Christopher J Rivard; David A Long
Journal:  Diabetes       Date:  2009-07       Impact factor: 9.461

7.  The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation.

Authors:  David M Roberts; Joseph B Kearney; Jennifer H Johnson; Michael P Rosenberg; Rakesh Kumar; Victoria L Bautch
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 8.  Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.

Authors:  Andrew J Krentz; Geraldine Clough; Christopher D Byrne
Journal:  Diabetes Obes Metab       Date:  2007-11       Impact factor: 6.577

Review 9.  A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism.

Authors:  T Nakagawa
Journal:  Clin Nephrol       Date:  2009-02       Impact factor: 0.975

10.  Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline.

Authors:  Nilka Ríos Burrows; Yanfeng Li; Linda S Geiss
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

View more
  26 in total

1.  C-peptide preserves the renal microvascular architecture in the streptozotocin-induced diabetic rat.

Authors:  Elizabeth R Flynn; Jonathan Lee; Zachary M Hutchens; Alejandro R Chade; Christine Maric-Bilkan
Journal:  J Diabetes Complications       Date:  2013-08-29       Impact factor: 2.852

Review 2.  Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury.

Authors:  Alejandro R Chade
Journal:  Hypertension       Date:  2017-02-13       Impact factor: 10.190

3.  Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.

Authors:  Takahiro Masuda; Yuko Watanabe; Keiko Fukuda; Minami Watanabe; Akira Onishi; Ken Ohara; Toshimi Imai; Hermann Koepsell; Shigeaki Muto; Volker Vallon; Daisuke Nagata
Journal:  Am J Physiol Renal Physiol       Date:  2018-05-23

4.  Vascular Endothelial Growth Factor Therapy for the Kidney: Are We There Yet?

Authors:  Alejandro R Chade
Journal:  J Am Soc Nephrol       Date:  2015-06-02       Impact factor: 10.121

Review 5.  Endothelial cell apoptosis in angiogenesis and vessel regression.

Authors:  Emma C Watson; Zoe L Grant; Leigh Coultas
Journal:  Cell Mol Life Sci       Date:  2017-06-23       Impact factor: 9.261

6.  Biopolymer-delivered vascular endothelial growth factor improves renal outcomes following revascularization.

Authors:  Erika Guise; Jason E Engel; Maxx L Williams; Fakhri Mahdi; Gene L Bidwell; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2019-03-20

Review 7.  Potential approaches to reverse or repair renal fibrosis.

Authors:  Desiree Tampe; Michael Zeisberg
Journal:  Nat Rev Nephrol       Date:  2014-02-11       Impact factor: 28.314

8.  Nephron Deficiency and Predisposition to Renal Injury in a Novel One-Kidney Genetic Model.

Authors:  Xuexiang Wang; Ashley C Johnson; Jan M Williams; Tiffani White; Alejandro R Chade; Jie Zhang; Ruisheng Liu; Richard J Roman; Jonathan W Lee; Patrick B Kyle; Leah Solberg-Woods; Michael R Garrett
Journal:  J Am Soc Nephrol       Date:  2014-10-27       Impact factor: 10.121

9.  Endothelial marker-expressing stromal cells are critical for kidney formation.

Authors:  Elina Mukherjee; Katherine Maringer; Emily Papke; Daniel Bushnell; Caitlin Schaefer; Rafael Kramann; Jacqueline Ho; Benjamin D Humphreys; Carlton Bates; Sunder Sims-Lucas
Journal:  Am J Physiol Renal Physiol       Date:  2017-05-24

10.  Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.

Authors:  Nathan A Tullos; Nicholas J Stewart; Ryan Davidovich; Alejandro R Chade
Journal:  Nephrol Dial Transplant       Date:  2014-11-21       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.